References
- Aksamija A, Horvat G Habek D, et al. (2009). Nitrofurantoin-induced acute liver damage in pregnancy. Arh Hig Rada Toksikol 60:357–61
- Aufrère MB, Hoener BA, Vore M. (1978). Reductive metabolism of nitrofurantoin in the rat. Drug Metab Dispos 6:403–11
- Black M, Rabin L, Schatz N. (1980). Nitrofurantoin-induced chronic active hepatitis. Ann Intern Med 92:62–4
- Ernaelsteen D, Williams R. (1962). Jaundice due to nitrofurantoin. Gastroenterology 41:590–3
- Bryan GT. (1978). In: Bryan GT, ed. Carcinogenesis – a comprehensive survey. Raven Press, New York, vol. 4, p. 1
- Fromowitz M, Shuga J Wlassowsky AY, et al. (2012). Bone marrow genotoxicity of 2,5-dimethylfuran, a green biofuel candidate. Environ Mol Mutagen 53:488–91
- Hatoff DE, Cohen M, Schweigert BF, Talbert WM. (1979). Nitrofurantoin: another cause of drug-induced chronic active hepatitis? A report of a patient with HLA-B8 antigen. Am J Med 67:117–21
- Jonen HG, Oesch F, Platt KL. (1980). 4-Hydroxylation of nitrofurantoin in the rat. A 3-methylcholanthrene-inducible pathway of a relatively nontoxic compound. Drug Metab Dispos 8:446–51
- Kelly BD, Heneghan MA Bennani F, et al. (1998). Nitrofurantoin-induced hepatotoxicity mediated by CD8+ T cells. Am J Gastroenterol 93:819–21
- Kiang TK, Ford JA, Yoshida EM, Partovi N. (2011). Nitrofurantoin-associated lung and liver toxicity leading to liver transplantation in a middle-aged patient. Can J Hosp Pharm 64:262–70
- Koulaouzidis A, Bhat S Moschos J, et al. (2007). Nitrofurantoin-induced lung- and hepatotoxicity. Ann Hepatol 6:119–21
- Lin D, Guo X Gao H, et al. (2015). In vitro and in vivo studies of the metabolic activation of 8-epidiosbulbin E acetate. Chem Res Toxicol 28:1737–46
- Lin D, Li C Peng Y, et al. (2014). Cytochrome P450-mediated metabolic activation of diosbulbin B. Drug Metab Dispos 42:1727–36
- Linnebur SA, Parnes BL. (2004). Pulmonary and hepatic toxicity due to nitrofurantoin and fluconazole treatment. Ann Pharmacother 38:612–6
- Minchin RF, Ho PC, Boyd MR. (1985). Reductive metabolism of nitrofurantoin by rat lung and liver in vitro. Biochem Pharmacol 35:575–80
- Moreno SN, Mason RP, Docampo R. (1983). Reduction of nifurtimox and nitrofurantoin to free radical metabolites by rat liver mitochondria. Evidence of an outer membrane-located nitroreductase. J Biol Chem 259:6298–305
- Peall AF, Hodges A. (2007). Concomitant pulmonary and hepatic toxicity secondary to nitrofurantoin: a case report. J Med Case Rep 1:59
- Phillips MB, Sullivan MM, Villalta PW, Peterson LA. (2014). Covalent modification of cytochrome c by reactive metabolites of furan. Chem Res Toxicol 27:129–35
- Rodrigues AD. (1999). Integrated cytochrome P450 reaction phenotyping: attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes. Biochem Pharmacol 57:465–80
- Sakaan SA, Twilla JD Usery JB, et al. (2014). Nitrofurantoin-induced hepatotoxicity: a rare yet serious complication. South Med J 107:107–13
- Sargın G, Elbek O Balantekin C, et al. (2012). Acute respiratory distress syndrome and hepatotoxicity associated with single dose nitrofurantoin use: a case report. Case Rep Pulmonol 2012:465389
- Taber DF, DeMatteo PW, Hassan RA. (2013). Simplified preparation of dimethyldioxirane (DMDO). Org Synth 90:350–7
- Tolman KG. (1980). Nitrofurantoin and chronic active hepatitis. Ann Intern Med 92:119–20
- U.S. Department of Health and Human Service, Food and Drug Administration. Guidance for industry on drug interaction studies. Silver Spring, MD. Available from: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm
- Wang K, Zheng L Peng Y, et al. (2014). Selective and sensitive platform for function-based screening of potentially harmful furans. Anal Chem 86:10755–62